Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20609907 | 0.89 | APLNR (0.36) | PIK3CAAPLNR | |
| SCHEMBL10254306 | 0.88 | PIK3CA (0.34) | PIK3CAAPLNR | |
| SCHEMBL12890366 | 0.83 | PIK3CA (0.32) | PIK3CAAPLNR | |
| SCHEMBL20635737 | 0.82 | HRH3 (0.32) | — | |
| SCHEMBL24261284 | 0.82 | PIK3CA (0.35) | PIK3CAJAK2JAK1 | |
| SCHEMBL20711788 | 0.82 | PIK3CA (0.35) | PIK3CAJAK2JAK1 | |
| SCHEMBL12206044 | 0.82 | PIK3CA (0.35) | PIK3CAJAK2JAK1 | |
| SCHEMBL20634470 | 0.80 | — | — | |
| SCHEMBL20634403 | 0.79 | APLNR (0.32) | APLNR | |
| SCHEMBL22198736 | 0.78 | JAK2 (0.38) | PIK3CAJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2025-04-10 | — | — | US | disclosed |
| US-11981667-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-05-14 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
| US-11465992-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2022-10-11 | — | — | US | disclosed |
| EP-3978489-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | Inflazome Limited (IE) | 2022-04-06 | — | — | EP | disclosed |
| EP-3661925-B1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2021-11-24 | — | — | EP | disclosed |
| EP-3661925-B1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2021-11-24 | — | — | EP | disclosed |
| US-20200291003-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20200291003-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | SYGNATURE DISCOVERY LIMITED (GB) | 2020-09-17 | — | — | US | disclosed |
| EP-3661925-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | Inflazome Limited (IE) | 2020-06-10 | — | — | EP | disclosed |
| CN-110914256-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-03-24 | — | — | CN | disclosed |
| WO-2019008025-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
| WO-2019008025-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | PIK3CA 2731/4885JAK2 2318/4885JAK1 2857/4885 |
| US-11981667-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, PYCARD | PIK3CA 3085/4885JAK2 1429/4885JAK1 1785/4885 |
| US-20250115591-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | PIK3CA 2964/4885JAK2 1443/4885JAK1 1640/4885 |
| US-20200291003-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | PIK3CA 2964/4885JAK2 1443/4885JAK1 1640/4885 |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | PIK3CA 3076/4885JAK2 1533/4885JAK1 1825/4885 |
| US-11465992-B2 | Sulfonamide carboxamide compounds | NLRP3, NOD1, PYCARD | PIK3CA 3123/4885JAK2 1301/4885JAK1 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.